Table 3 Relationship between of CYBB expression and clinical characteristics of patients with CESC
Gene | Characteristics | Total (N) | Odds ratio (OR) | P value |
|---|---|---|---|---|
CYBB | Age (≤ 50 vs. > 50) | 304 | 0.865 (0.723–1.030) | 0.106 |
BMI (≤ 25 vs. > 25) | 259 | 0.970 (0.801–1.172) | 0.750 | |
Menopause status (Pre vs. Peri and Post) | 231 | 0.956 (0.783–1.166) | 0.654 | |
Histological type (adenosquamous vs. squamous cell carcinoma) | 304 | 0.541 (0.411–0.699) |  < 0.001 | |
T stage (T1 and T2 vs. T3 and T4) | 241 | 1.098 (0.823–1.474) | 0.526 | |
N stage (N0 vs. N1) | 193 | 0.936 (0.741–1.180) | 0.576 | |
M stage (M0 vs. M1) | 126 | 1.649 (1.000–2.817) | 0.055 | |
Clinical stage (stage I and stage II vs. stage IV and stage III) | 297 | 1.072 (0.873–1.321) | 0.509 | |
Histologic grade (G1 and G2 vs. G4 and G3) | 272 | 0.843 (0.702–1.009) | 0.065 | |
Primary therapy outcome (SD and PR and CR vs. PD) | 217 | 1.397 (0.997–1.991) | 0.057 | |
Radiation therapy (yes vs. no) | 304 | 1.074 (0.902–1.280) | 0.424 |